Market news

MannKind (NASDAQ:MNKD) CFO Chris Prentiss outlined the company’s commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase

On September 9, MannKind Corporation (NASDAQ:MNKD) announced a licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere, an inhaled, rapid-acting glucagon-like peptide-1 receptor agonist aimed at weight management. The deal hands MannKind an equity stake in Rose Pharma, a board seat, and royalty rights on future sales, without saddling it with the […]

MannKind and Rose Pharma are partnering to develop an inhaled weight-loss treatment using the Technosphere dry-powder inhalation technology.

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere® inhalation technologyMannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, pat

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that members of the MannKind management team will present at the following upcoming investor conferences: Cantor Global Healthcare Conference (New York, NY)Fireside Chat, Thursday, September 10, 2026, at 11:30 a.m. ET H.C. Wainwright 28th Annual Global Investment Conference (New York, NY)Fireside Chat, Tuesday, September 15, 2026, at 9:30 a.m. ET Links to the live

MannKind (MNKD) continues to draw attention after recent share price moves, with the stock closing at US$3.95. Investors are weighing its current market value of about US$1.31b against its latest financial profile. Over the past year, MannKind’s share price return has been weak compared with its recent 30 day and 90 day share price returns of 2.60% and 4.77%, while the 1 year total shareholder return declined 13.94%. This suggests that recent momentum is still trying to repair longer term...

MannKind Corp (MNKD) reports 43% revenue surge to $109.4 million, fueled by Furosix momentum and Afrezza pediatric launch, despite a GAAP net loss.

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

MannKind (MNKD) delivered earnings and revenue surprises of -200.00% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza® following FDA approvalFUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKDPositive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement Encouraging early momentum in Afrezza pediatric launch 1 in 3 of the top 100 pediatric insulin writers have prescribed Q2 2026 total revenues of $109.4M, +43% vs. Q2 2025Conference call and webcast today a

MannKind (NASDAQ:MNKD) reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs. The company recorded a GAAP net loss of $19

2026-07-30. The following slide deck was published by MannKind Corporation in conjunction with this event.

Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough~450 total inhalations administered in patients with IPFGlobal Phase 2 INFLO-2 trial actively enrolling patientsConference call and webcast scheduled for July 29 at 4:30 p.m. ET DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on devel

MannKind (NASDAQ:MNKD) reported Phase 1b results for its inhaled nintedanib dry-powder inhalation, or DPI, candidate in patients with idiopathic pulmonary fibrosis, or IPF, saying the seven-day study met its objective of demonstrating short-term safety and tolerability. The company’s INFLO-1 trial

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that the Company will report second quarter 2026 financial results after market close on Wednesday, August 5, 2026. MannKind’s management team will host a conference call at 4:30 p.m. Eastern Time to review the financial results and provide a business update. The webcast of the conference call will be accessible via a link on MannKind’s website at https://investors.

Mannkind Corporation shares are trading higher as the company recently announced the U.S. Food and Drug Administration’s (FDA) approval of Furoscix ReadyFlow, an at-home treatment option for adults with heart failure or chronic kidney disease. MannKind (MNKD) Jumps On FDA...

Detailed price information for Mannkind Corp (MNKD-Q) from The Globe and Mail including charting and trades.

MannKind (MNKD) is in focus after the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure or chronic kidney disease, alongside a roughly $50 million private placement. See our latest analysis for MannKind. The FDA approval of Furoscix ReadyFlow and the roughly $50 million private placement come after a mixed period for MannKind, with a 90 day share price return of 52.96% but a year to date share price decline of 26.25%,...

MannKind Corporation has now received U.S. FDA approval for Furoscix ReadyFlow, an at-home autoinjector delivering an IV‑equivalent 80 mg/mL furosemide dose in under 10 seconds to treat edema in adults with heart failure or chronic kidney disease. This second Furoscix presentation could materially extend MannKind’s reach beyond hospitals into outpatient and home-based fluid management, broadening its cardiology and nephrology footprint. We’ll now examine how launching an at-home...

MannKind stock rose after the FDA approved Furoscix ReadyFlow, as the company also announced a $50 million private placement financing.

MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds for the management of fluid overload. Chief Executive Officer Michael Castagna said the approval

MannKind Corporation (NASDAQ:MNKD) shares climbed around 6% on Friday after the biotechnology company announced U. S.

The FDA is expected to announce its decision on MannKind’s sNDA on July 26, 2026.

Furoscix ReadyFlow [prototype] The U.S. FDA has approved Furoscix ReadyFlow (furosemide injection) for the treatment of edema (fluid overload) in adults with heart failure or chronic kidney disease. Transformative delivery option that may support earlier management of worsening fluid overload with a self-administered option designed for use outside the hospital settingDelivers IV-equivalent diuretic effect through a simple, ready-to-use autoinjectorProvides an 80 mg/mL furosemide dose in a singl